Hepatotoxic Effects of Lipid-Altering Agents

被引：0
|
作者：
Korth, Christine E. [1 ]
Backes, James M. [2 ,3 ]
机构：
[1] Nebraska Med Ctr, Omaha, NE 68198 USA
[2] Univ Kansas, Med Ctr, Sch Pharm & Med, Pharm Practice, Kansas City, KS 66103 USA
[3] Univ Kansas, Med Ctr, Atherosclerosis & LDL Apheresis Ctr, Kansas City, KS 66103 USA
来源：
US PHARMACIST | 2012年 / 37卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：HS17 / HS20
页数：4
相关论文
共 50 条
  • [41] An interim analysis of the lipid-altering effects of the dietary supplement pantethine (Retraction of vol 18, pg A910, 2004)
    First, S. M.
    Pins, J. J.
    Shamilyan, T.
    Keenan, J. M.
    FASEB JOURNAL, 2009, 23 (05): : 1616 - 1616
  • [42] THE EFFECT OF HEPATOTOXIC AGENTS ON LIPID MOBILIZED FROM THE DEPOTS
    SEIFTER, J
    BAEDER, DH
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1958, 122 (01): : A67 - A67
  • [43] KHELLIN ANALOGS .1. GENERAL TOPOLOGICAL REQUIREMENTS FOR LIPID-ALTERING ACTIVITY IN FUROCHROMONES
    GAMMILL, RB
    DAY, CE
    SCHURR, PE
    JOURNAL OF MEDICINAL CHEMISTRY, 1983, 26 (12) : 1672 - 1674
  • [44] Lipid-altering Efficacy of Ezetimibe/Simvastatin Compared with Rosuvastatin in Hypercholesterolaemic Patients: A Meta-Analysis
    Liu, Yongming
    Xia, Nan
    Hu, Wanying
    Zhao, Wei
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2019, 15 (02) : 200 - 208
  • [45] Lipid-altering efficacy and tolerability of ER niacin/laropiprant in type 2 diabetes mellitus patients
    Maclean, A.
    Mckenney, J.
    Scott, R.
    Brinton, E.
    Bays, H.
    Giezek, H.
    Ruck, R.
    Gibson, K.
    Sisk, C. Mccrary
    Maccubbin, D.
    EUROPEAN HEART JOURNAL, 2009, 30 : 298 - 298
  • [46] Lipid-altering efficacy of extended-release niacin/laropiprant in dyslipidaemic patients with metabolic syndrome
    Bays, H. E.
    Maccubbin, D. L.
    Shah, A. K.
    Lin, J.
    Sisk, C. M.
    Paolini, J. F.
    DIABETOLOGIA, 2008, 51 : S558 - S558
  • [47] TREATMENT PATTERNS WITH LIPID-ALTERING DRUGS IN HIGH-RISK VASCULAR DISEASE IN THE UNITED KINGDOM
    Zhao, Z.
    Zhu, Y.
    Collins, J.
    Donaldson, R.
    Engelman, W.
    Nordstrom, B.
    VALUE IN HEALTH, 2014, 17 (03) : A122 - A122
  • [48] Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century.
    Jacobson T.A.
    Current Atherosclerosis Reports, 2001, 3 (5) : 373 - 382
  • [49] Are 20-hydroxyecdysone and related genes potential biomarkers of sublethal exposure to lipid-altering contaminants?
    Hugo Alarie
    Nadia Côté
    Luc Gaudreau
    Magali Houde
    Pedro A. Segura
    Environmental Science and Pollution Research, 2023, 30 : 126104 - 126115
  • [50] Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH
    Oniciu, Daniela Carmen
    Hashiguchi, Taishi
    Shibazaki, Yuichiro
    Bisgaier, Charles L.
    PLOS ONE, 2018, 13 (05):
12345